News >

Targeted Agents Transforming AML Paradigm

Nichole Tucker
Published: Wednesday, Jul 24, 2019

Elias Jabbour, MD

Elias Jabbour, MD

The FDA approval of multiple targeted agents in recent years is transforming the treatment landscape in acute myeloid leukemia (AML), explained Elias Jabbour, MD, professor of medicine, Department of Leukemia, MD Anderson Cancer Center.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Medical Crossfire®: BiTE Technology Around the Globe: Improving Outcomes for Patients With Acute Lymphoblastic LeukemiaSep 28, 20192.0
Publication Bottom Border
Border Publication